A Phase I Trial of Sirolimus with “7&3” Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia

SIMPLE SUMMARY: Relapsed or refractory AML remains common and difficult to treat, with no standard of care. Therefore, improving upfront therapy to prevent relapse in younger AML patients who are candidates for aggressive chemotherapy is an imperative. The PI3K/AKT/mTOR pathway helps regulate a vari...

Descripción completa

Detalles Bibliográficos
Autores principales: Palmisiano, Neil, Jeschke, Grace, Wilde, Lindsay, Alpdogan, Onder, Carabasi, Matthew, Filicko-O’Hara, Joanne, Grosso, Dolores, Klumpp, Thomas, Martinez, Ubaldo, Wagner, John, Carroll, Martin P., Perl, Alexander, Kasner, Margaret
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10650097/
https://www.ncbi.nlm.nih.gov/pubmed/37958304
http://dx.doi.org/10.3390/cancers15215129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10650097/
https://www.ncbi.nlm.nih.gov/pubmed/37958304
http://dx.doi.org/10.3390/cancers15215129

Ejemplares similares